In patients with HIV-infection, chromium supplementation improves insulin resistance and other metabolic abnormalities: A randomized, double-blind, placebo controlled trial

Current HIV Research

Volumn 8, Issue 2, 2010, Pages 113-120

  Aghdassi, Elaheh ^a   Arendt, Bianca M ^a   Salit, Irving E ^a   Mohammed, Saira S ^b   Jalali, Pegah ^a   Bondar, Helena ^a   Allard, Johane P ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Body composition; Body fat redistribution; Chromium; Glucose; HIV; Insulin resistance

Indexed keywords

C PEPTIDE; CHROMIUM; CHROMIUM NICOTINATE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHEMICAL PARAMETERS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC DISORDER; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; TREATMENT OUTCOME;

BLOOD CHEMICAL ANALYSIS; BODY COMPOSITION; BODY WEIGHT; DIET; DIETARY SUPPLEMENTS; FEMALE; HIV; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC DISEASES; MIDDLE AGED; PICOLINIC ACIDS; TREATMENT OUTCOME;

EID: 77949716641     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210790442687     Document Type: Article

References (54)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
2. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30: 113-9.
3. Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 1997; 36: 4382-5.
4. Morris BW, Kouta S, Robinson R, MacNeil S, Heller S. Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. Diabetes Med 2000; 17: 684-5.
5. Aghdassi E, Salit IE, Fung L, Sreetharan L, Walmsley S, Allard JP. Is chromium an important element in HIV-positive patients with metabolic abnormalities? An hypothesis generating pilot study. J Am Coll Nutr 2006; 25: 56-63.
6. Dubois F, Belleville F. [Chromium: physiologic role and implications in human pathology]. Pathol Biol (Paris) 1991; 39:801-8.
7. Feiner JJ, McNurlan MA, Ferris RE, Mynarcik DC, Gelato MC. Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study. Diabetes Obes Metab 2008; 10: 151-8.
8. Brady LM, Gower BA, Lovegrove SS, Williams CM, Lovegrove JA. Revised QUICKI provides a strong surrogate estimate of insulin sensitivity when compared with the minimal model. Int J Obes Relat Metab Disord 2004; 28: 222-7.
9. Blass SC, Ellinger S, Vogel M, et al. Overweight HIV patients with abdominal fat distribution treated with protesase inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control. Eur J Med Res 2008; 13: 209-14.
10. Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the highmolecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29: 1357-62.
11. Seino Y, Hirose H, Saito I, Itoh H. High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism 2007; 56: 1493-9.
12. Lee RD, Nieman DC. Nutritional Assessment. New York, McGraw Hill 2003.
13. Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K. Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA Project. Int J Obes Relat Metab Disord 1999; 23: 116-25.
14. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-10.
15. Millen B, Morgan JL. The 2D Food Portion Visual. Framingham, Nutrition Consulting Enterprises 1996.
16. World Health Organization, Food and Agriculture Organization of the United Nations. Preparation and use of food-based dietary guidelines. Chapter Three - Methods of monitoring food & nutrient intake. Report of a joint FAO/WHO Consultation, Nicosia, Cyprus. Accessible online August 12, 2008: http://www.fao.org/DOCREP/x0243e/x0243e00.htm. Geneva, World Health Organization. 1996.
17. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997; 20: 537-44.
18. Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006; 29: 1826-32.
19. Wang ZQ, Qin J, Martin J, et al. Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metabolism 2007; 56: 1652-5.
20. Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a metaanalysis. Am J Clin Nutr 2002; 76: 148-55.
21. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997; 46: 1786-91.
22. Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007; 30: 2154-63.
23. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004; 27: 2741-51.
24. Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977; 30: 531-8.
25. Kleefstra N, Houweling ST, Jansman FG, et al. Chromium treatment has no effect in patients with poorly controlled, insulintreated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2006; 29: 521-5.
26. Levine RA, Streeten DH, Doisy RJ. Effects of oral chromium supplementation on the glucose tolerance of elderly human subjects. Metabolism 1968; 17: 114-25.
27. Anderson RA. Recent advances in the clinical and biochemical effects of chromium deficiency. Prog Clin Biol Res 1993; 380: 221-34.
28. Anderson RA. Chromium, glucose tolerance, diabetes and lipid metabolism. J Adv Med 1995; 8: 37-49.
29. Anderson RA, Bryden NA, Polansky MM, Reiser S. Urinary chromium excretion and insulinogenic properties of carbohydrates. Am J Clin Nutr 1990; 51: 864-8.
30. Anderson RA, Polansky MM, Bryden NA, Roginski EE, Mertz W, Glinsmann W. Chromium supplementation of human subjects: effects on glucose, insulin, and lipid variables. Metabolism 1983; 32: 894-9.
31. Brown RO, Forloines-Lynn S, Cross RE, Heizer WD. Chromium deficiency after long-term total parenteral nutrition. Dig Dis Sci 1986; 31: 661-4.
32. Freund H, Atamian S, Fischer JE. Chromium deficiency during total parenteral nutrition. JAMA 1979; 241: 496-8.
33. Glinsmann WH, Mertz W. Effect of trivalent chromium on glucose tolerance. Metabolism 1966; 15: 510-20.
34. Mertz W. Chromium in human nutrition: a review. J Nutr 1993; 123: 626-33.
35. Riales R, Albrink MJ. Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. Am J Clin Nutr 1981; 34: 2670-8.
36. Schwarz K, Mertz W. Chromium(III) and the glucose tolerance factor. Arch Biochem Biophys 1959; 85: 292-5.
37. Gurson CT, Saner G. Effect of chromium on glucose utilization in marasmic protein-calorie malnutrition. Am J Clin Nutr 1971; 24: 1313-9.
38. Hopkins LL, Jr., Ransome-Kuti O, Majaj AS. Improvement of impaired carbohydrate metabolism by chromium 3 in manourished infants. Am J Clin Nutr 1968; 21: 203-11.
39. Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism 1992; 41: 768-71.
40. Press RI, Geller J, Evans GW. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. West J Med 1990; 152: 41-5.
41. Sax PE, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004; 37: 1111-24.
42. Moyle G, Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials 2002; 3: 89-98.
43. Matsuzawa Y, Nakamura T, Shimomura I, Kotani K. Visceral fat accumulation and cardiovascular disease. Obes Res 1995; 3: 645S-7S.
44. Falutz J, Allas S, Kotler D, et al. A placebo-controlled, doseranging study of a growth hormone releasing factor in HIVinfected patients with abdominal fat accumulation. AIDS 2005; 19: 1279-87.
45. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008; 300: 509-19.
46. Macallan DC, Baldwin C, Mandalia S, et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 2008; 9: 254-68.
47. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006; 91: 2605-11.
48. Evans GW. The effect of chromium picolinate on insulin controlled parameters in humans. Int J Biosoc Med Res 1989; 11: 163-80.
49. Lukaski HC, Siders WA, Penland JG. Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. Nutrition 2007; 23: 187-95.
50. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
51. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabet Care 1998; 21: 2191-2.
52. HOMA 2 Calculator, v 2.2.2. Diabetes Trials Unit, University of Oxford. Accessible online July 15, 2009: http://www.dtu.ox.ac.uk/homa. Oxford, University of Oxford. 2007.
53. Anderson RA, Kozlovsky AS. Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am J Clin Nutr 1985; 41: 1177-83.
54. Offenbacher EG. Chromium in the elderly. Biol Trace Elem Res 1992; 32: 123-31.